| abstract |
Combined use of a proteasome activity inhibitor with an anticancer agent containing a topoisomerase activity inhibitor makes it possible to inhibit t he proteasome activity of promoting the degradation of topoisomerase. Thus, the presence of a sufficient amount of topoisomerase can be ensured in cancer cells and the effect of the anticancer agent containing the topoisomerase activity inhibitor targeted on topoisomerase can be potentiated. Similarly, combined use of a proteasome activity inhibitor with DNA strand-injury type anticancer agents (for example, platinum complexes, alkylating agents, bleomycins), which directly act on DNA but suffer from regulation or reducti on in the effects thereof by the proteasome activity, can potentiate the effect s. |